Argenx SE: Excellent Company, Premium Valuation
Source: SeekingAlpha
2026-03-10 09:50:29 ET
Introduction
argenx SE ( ARGX ) is one of the most successful commercial biotech stories in recent years. VYVGART (efgartigimod), its flagship FcRn inhibitor, has become a multi-billion blockbuster, rapidly transforming the entire treatment landscape in myasthenia gravis ( MG ). In 2025, VYVGART total product sales were $4.2 billion, up 90% year over year. Q4 revenue was $1.3 billion. They are already operationally profitable, with $4.4 billion in cash on the balance sheet....
Read the full article on Seeking Alpha
For further details see:
Argenx SE: Excellent Company, Premium Valuation
argenx SE
NASDAQ: ARGX
ARGX Trading
-1.64% G/L:
$732.4625 Last:
208,986 Volume:
$743.84 Open:
ARGX Latest News
March 06, 2026 01:00:00 am
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
February 26, 2026 01:00:00 am
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
February 26, 2026 12:30:00 am
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
ARGX Stock Data
$51,240,248,691
60,277,264
N/A
217
N/A
Biotechnology & Life Sciences
Healthcare
NL
Amsterdam
